ReviewJournal of clinical immunology1999
Chemokines as molecular targets for therapeutic intervention.
Review in Journal of clinical immunology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 52 citations in OpenAlex.
- Interactive Effects of Morphine on HIV Infection: Role in HIV-Associated Neurocognitive Disorder.AIDS research and treatment · 2012Article
- Regio- and stereoselective syntheses of the natural product CCR5 antagonist anibamine and its three olefin isomers.The Journal of organic chemistry · 2011Article
- NOP Receptor Ligands as Potential Agents for Inflammatory and Autoimmune Diseases.Journal of amino acids · 2011Article
- Comparative docking study of anibamine as the first natural product CCR5 antagonist in CCR5 homology models.Journal of chemical information and modeling · 2009Article
- Enzymatic digestion of the milk protein beta-casein releases potent chemotactic peptide(s) for monocytes and macrophages.International immunopharmacology · 2007Article
- Rapid heterologous desensitization of antinociceptive activity between mu or delta opioid receptors and chemokine receptors in rats.Drug and alcohol dependence · 2007Article
- Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
- Gene- and cell-based therapeutics for type I diabetes mellitus.Gene therapy · 2003Review
- Response of chemokine antagonists to inflammation in injured spinal cord.Neurochemical research · 2003Review
- Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours.British journal of cancer · 2001Article
- Chemokine receptor 1 knockout abrogates natural killer cell recruitment and impairs type-1 cytokines in lymphoid tissue during pulmonary granuloma formation.The American journal of pathology · 2000Article
- Opioid and nociceptin receptors regulate cytokine and cytokine receptor expression.Cellular immunologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Despite the youth of the chemokine field, many antagonists of chemokine function have already been identified and tested at the preclinical level. These include neutralizing antibodies, peptidyl and non-peptidyl antagonists and non-specific immunosuppressive agents. These early studies suggest that chemokine agonists have the potential to regulate many diseases, ranging from HIV-1 infection and tumor growth to acute and chronic inflammation. Clinical application will depend on pharmaceutical development. Great strides have been made in defining structural domains of the chemokines involved in receptor binding and activation. The identification of receptors is rapidly progressing, but with 50 potential ligands and 15 characterized receptors, it is obvious that additional molecular studies are needed. The intriguing observation that several pathogens either use chemokine receptors as entry portals or produce chemokine decoys to subvert the immune system suggests that there is much to be learned about the immune system from studies of "virokines." Future studies should lead to the discovery and design of more effective inhibitors and antagonists with therapeutic benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.